Start a patient | SKYTROFA® (lonapegsomatropin-tcgd) The FRM can also help with appeals submissions in the event of coverage denial (s) In addition, the A·S·A·P team can check to see if your patient is eligible to receive a 4-week supply of SKYTROFA and the SKYTROFA Auto-Injector through the FastStart Program, and initiate enrollment if they are eligible
Skytrofa Coupon 2026 | Savings Card | PrescriberPoint The Skytrofa FastStart Program is designed to support patients who are prescribed the drug Skytrofa This program offers a significant benefit by providing a 4-week supply of Skytrofa and the SKYTROFA® Auto-Injector to commercially insured patients experiencing treatment delays due to denied coverage
Self-Pay Program | SKYTROFA® (lonapegsomatropin-tcgd) Another way to access SKYTROFA As part of our commitment to the pediatric growth hormone community, we offer the only comprehensive self-pay program among weekly growth hormone treatment options How it works: Once your child is prescribed SKYTROFA, their doctor will enroll them in the Self Pay Program Have questions? Contact the A·S·A·P team at 1-844-442-7236
Study Details | NCT07221851 | Trial Investigating the . . . This basket trial will enroll prepubertal children and adolescents with clinically diagnosed and genetically confirmed (if applicable) TS, SHOX-D, SGA, or ISS between ages of ≥2 and <18 years with open growth plates The purpose of the study is to see how well treatment with once-weekly lonapegsomatropin works compared to treatment with daily somatropin Approximately 186 participants will
SKYTROFA (lonapegsomatropin-tcgd) for injection, for . . . SKYTROFA (lonapegsomatropin-tcgd) for injection is a sterile, preservative-free, white to off-white lyophilized powder available in a single-dose, dual-chamber, prefilled cartridge containing lonapegsomatropin-tcgd in one chamber and the diluent, Water for Injection, in the second chamber
SKYTROFA 4. 3 MG CARTRIDGE - 4EA | Vendor Drug Program * Impacts only claims paid by HHSC: traditional Medicaid, CSHCN, HTW, and KHC Programs † Refer to the Specialty Drug Handbook for more information ‡ Refer to the “Premium Preferred Generic Drugs section” of the Pharmacy Provider Procedure Manual for information about traditional Medicaid claim pricing incentives
SKYTROFA® (Lonapegsomatropin-tcgd) Now Available in Broader . . . About SKYTROFA Administration The SKYTROFA® Auto-Injector and cartridges are uniquely designed to deliver a full week’s dose and minimize the potential for wasted medication with no split dosing or dose dialing and no exposed needles during injections
Ascendis Pharma A S (ASND) FDA Approvals - MarketBeat Ascendis Pharma A S's Drugs in the FDA Approval Process This section highlights FDA-related milestones and regulatory updates for drugs developed by Ascendis Pharma A S (ASND) Over the past two years, Ascendis Pharma A S has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as TransCon, TransCon, TransCon, SKYTROFA